Skip to Content

New Drug Approvals Archive - April 2003

April 2003

April 4

Iprivask (desirudin) Injection

Date of Approval: April 4, 2003
Company: Aventis Pharmaceuticals, Inc
Treatment for: Deep Vein Thrombosis -- Prophylaxis

Iprivask (desirudin) is a specific inhibitor of human thrombin indicated for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, in patients undergoing elective hip replacement surgery.

April 4

Factive (gemifloxacin) Tablets

Date of Approval: April 4, 2003
Company: LG Life Sciences, Ltd
Treatment for: Bacterial Infection

Factive (gemifloxacin) is a fluoroquinolone antibiotics indicated for the treatment of community-acquired pneumonia and acute bacterial exacerbation of chronic bronchitis.

April 15

Vigamox (moxifloxacin) Ophthalmic Solution

Date of Approval: April 15, 2003
Company: Alcon
Treatment for: Bacterial Conjunctivitis

Vigamox (moxifloxacin) is a fourth generation fluoroquinilone antibiotic indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of bacteria.

April 24

Fabrazyme (agalsidase beta)

Date of Approval: April 24, 2003
Company: Genzyme Corp
Treatment for: Fabry Disease

Fabrazyme (agalsidase beta) is a recombinant form of human alpha-galactosidase A, administered intravenously for the treatment of Fabry Disease.

April 30

Aldurazyme (laronidase)

Date of Approval: April 30, 2003
Company: Biomarin Pharmaceutical
Treatment for: Mucopolysaccharidosis Type I

Aldurazyme (laronidase) is recombinant human alpha-L-iduronidaseis indicated for the treatment of mucopolysaccharidosis I (MPS I).

New Drug Approvals Archive